[1] WILLISON HJ, JACOBS BC, VAN DOORN PA. Guillain-Barré syndrome[J]. The Lancet, 2016, 388(10045): 717. doi: 10.1016/S0140-6736(16)00339-1
[2] POLITO A, POLITO A, BOUCHEREAU E, et al. Dysglycemia and neurologic outcome in mechanically ventilated patients with Guillain-Barre syndrome[J]. Crit Care Med, 2019, 47(3): e227. doi: 10.1097/CCM.0000000000003635
[3] WANG Y, LI G, YANG S, et al. Fasting glucose levels correlate with disease severity of Guillain-Barre syndrome[J]. PLoS One, 2015, 10(12): e0145075. doi: 10.1371/journal.pone.0145075
[4] CAPASSO A, OMPAD DC, VIEIRA DL, et al. Incidence of Guillain-Barré Syndrome(GBS) in Latin America and the Caribbean before and during the 2015-2016 Zika virus epidemic: A systematic review and meta-analysis[J]. PLoS Negl Trop Dis, 2019, 13(8): e0007622. doi: 10.1371/journal.pntd.0007622
[5] WACHIRA VK, PEIXOTO HM, DE OLIVEIRA MRF. Systematic review of factors associated with the development of Guillain-Barré syndrome 2007-2017: what has changed[J]. Trop Med Int Health, 2019, 24(2): 132. doi: 10.1111/tmi.13181
[6] LEONHARD SE, MANDARAKAS MR, GONDIM FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps[J]. Nat Rev Neurol, 2019, 15(11): 671. doi: 10.1038/s41582-019-0250-9
[7] MICHALEK RD, GERRIETS VA, JACOBS SR, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets[J]. J Immunol, 2011, 186(6): 3299. doi: 10.4049/jimmunol.1003613
[8] FELDMAN EL, CALLAGHAN BC, POP-BUSUI R, et al. Diabetic neuropathy[J]. Nat Rev Dis Primers, 2019, 5(1): 41. doi: 10.1038/s41572-019-0092-1
[9] DUNNIGAN SK, EBADI H, BREINER A, et al. Conduction slowing in diabetic sensorimotor polyneuropathy[J]. Diabetes Care, 2013, 36(11): 3684. doi: 10.2337/dc13-0746
[10] DONATH MY, DALMAS E, SAUTER NS, et al. Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity[J]. Cell Metab, 2013, 17(6): 860. doi: 10.1016/j.cmet.2013.05.001
[11] SUN T, CHEN X, SHI S, et al. Peripheral blood and cerebrospinal fluid cytokine levels in Guillain Barre syndrome: a systematic review and meta-analysis[J]. Front Neurosci, 2019, 13: 717. doi: 10.3389/fnins.2019.00717
[12] LIU J, LIAN Z, CHEN H, et al. Associations between tumor necrosis factor-α gene polymorphisms and the risk of Guillain-Barré syndrome and its subtypes: A systematic review and meta-analysis[J]. J Neuroimmunol, 2017, 3(13): 25.
[13] JEONG H, BAEK SY, KIM SW, et al. C reactive protein level as a marker for dyslipidaemia, diabetes and metabolic syndrome: results from the Korea National Health and Nutrition Examination Survey[J]. BMJ Open, 2019, 9(8): e029861. doi: 10.1136/bmjopen-2019-029861
[14] DOTTA F, FALORNI A, TIBERTI C, et al. Autoantibodies to the GM2-1 islet ganglioside and to GAD-65 at type 1 diabetes onset[J]. J Autoimmun, 1997, 10(6): 585. doi: 10.1006/jaut.1997.0166
[15] FERNYHOUGH P, WILLARS GB, LINDSAY RM, et al. Insulin and insulin-like growth factor I enhance regeneration in cultured adult rat sensory neurones[J]. Brain Res, 1993, 607(1/2): 117.
[16] BRUSSEE V, CUNNINGHAM FA, ZOCHODNE DW. Direct insulin signaling of neurons reverses diabetic neuropathy[J]. Diabetes, 2004, 53(7): 1824. doi: 10.2337/diabetes.53.7.1824
[17] AFFES L, ELLEUCH M, MNIF F, et al. Guillain Barre syndrome and diabetic acido-ketotic decompensation during pregnancy: a case report and review of the literature[J]. Pan Afr Med J, 2017, 26: 86.
[18] VERBOON C, DOETS AY, GALASSI G, et al. Current treatment practice of Guillain-Barré syndrome[J]. Neurology, 2019, 93(1): e59. doi: 10.1212/WNL.0000000000007719
[19] HUGHES RA, BRASSINGTON R, GUNN AA, et al. Corticosteroids for Guillain-Barre syndrome[J]. Cochrane Database Syst Rev, 2016, 10: CD001446.
[20] LIU RT, ZHANG M, YANG CL, et al. Enhanced glycolysis contributes to the pathogenesis of experimental autoimmune neuritis[J]. J Neuroinflammation, 2018, 15(1): 51. doi: 10.1186/s12974-018-1095-7